Recent Updates
Recently added Catalysts

Biliary Tract Cancer: 4 biotech companies with clinical-stage programmes

OncologyConcentrated betData as of 2026-09-04

Competitors4in the clinic
Median market cap$7.4Buniverse median $1.20B
Allocated capital$4.6B$31.4B competing
Phase 3 or filed12 mid, 1 early
Pure plays0this indication only
Capital rank39/299crowding rank 46

Biliary Tract Cancer is a concentrated bet: only 4 US-listed developers are in the clinic, and the median one is worth $7.4B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

JAZZ carries 51% of the $31.4B competing here, more than the other 3 companies combined.

$4.6B of allocated capital sits in Biliary Tract Cancer, ranking it 39th of 299 indications by the money committed to it.

Companies developing drugs for Biliary Tract Cancer 4

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
JAZZJazz PharmaceuticalsZanidatamabPhase 31$16.1BNo14 30 Sep 2026
SMMTSummit TherapeuticsivonescimabPhase 21$13.7BNo5 14 Nov 2026
CMPXCompass TherapeuticsCTX-009Phase 21$427MNo3 24 Oct 2026
OPKOPKO HealthMDX2001Phase 11$1.2BNo2 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. JAZZ holds 51% of the $31.4B competing in this indication.

Why Biliary Tract Cancer is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Biliary Tract Cancer has 4 competitors and a median of $7.4B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Well-differentiated Non-functional Neuroendocrine Tumor1 company · $4.5B · median $9.0BUncontestedHead and Neck Cancer7 companies · $5.5B · median $1.8BGold rushChronic Lymphocytic Leukemia4 companies · $3.7B · median $2.1BConcentrated betGastric Cancer8 companies · $3.6B · median $575MKnife fightRenal Cell Carcinoma5 companies · $3.4B · median $3.8BConcentrated betColorectal Cancer7 companies · $5.9B · median $723MKnife fightHER2 Positive Breast Cancer2 companies · $3.3B · median $10.2BConcentrated betBladder Cancer with FGFR3 Mutation1 company · $3.3B · median $6.6BUncontested

Biliary Tract Cancer pipeline questions

Which biotech companies are developing drugs for Biliary Tract Cancer?

Jazz Pharmaceuticals (JAZZ, Zanidatamab, Phase 3); Summit Therapeutics (SMMT, ivonescimab, Phase 2); Compass Therapeutics (CMPX, CTX-009, Phase 2); OPKO Health (OPK, MDX2001, Phase 1). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Biliary Tract Cancer.

How advanced is the Biliary Tract Cancer pipeline?

Of the 4 clinical-stage programmes in Biliary Tract Cancer, 1 is in Phase 3 or filed, 2 are in mid-stage development and 1 is in early-stage development.

Which company leads the Biliary Tract Cancer field?

JAZZ is the largest developer in Biliary Tract Cancer, holding 51% of the $31.4B of market capitalisation competing in the indication. The median competitor is worth $7.4B.

When is the next Biliary Tract Cancer catalyst?

The next dated catalyst in Biliary Tract Cancer is JAZZ on 30 Sep 2026. 4 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map